ArticleNature biotechnology2011
A targeted proteomics-based pipeline for verification of biomarkers in plasma.
Article in Nature biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed.
- Affinity proteomics reveals elevated muscle proteins in plasma of children with cerebral malaria.PLoS pathogens · 2014Trial
- Biomarkers in Disease Diagnosis and Monitoring: Insights into Clinical Applications and Mass Spectrometry-based Detection.Applied biochemistry and biotechnology · 2026Review
- Metabolic Disruption in Osteoporotic Sheep: Evaluating Vitamin D Deficiency and Cortisone Effects via Biochemical Markers.Nutrients · 2025Article
- Proteomics Approaches for Discovering Novel Protein Biomarkers in Inflammatory Bowel Disease-Related Cancer.Biomolecules · 2025Review
- Article
- Advancing Newborn Screening in Washington State: A Novel Multiplexed LC-MS/MS Proteomic Assay for Wilson Disease and Inborn Errors of Immunity.International journal of neonatal screening · 2025Article
- Salivary Proteomics & Gene Expression Analysis: Applications in Orthodontics and Oral Health Care Research-A Pilot Project.Biomarker insights · 2025Article
- Clinical glycoproteomics: methods and diseases.MedComm · 2024Review
- Targeted Quantification of Proteoforms in Complex Samples by Proteoform Reaction Monitoring.Analytical chemistry · 2024Article
- Proteomic discovery of prognostic protein biomarkers for persisting problems after mild traumatic brain injury.Scientific reports · 2023Article
- Challenges and Opportunities for Single-cell Computational Proteomics.Molecular & cellular proteomics : MCP · 2023Review
- Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.Cancer discovery · 2023Article
- Using SILAC to Develop Quantitative Data-Independent Acquisition (DIA) Proteomic Methods.Methods in molecular biology (Clifton, N.J.) · 2023Article
- A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification.Frontiers in oncology · 2023Article
- Article
- A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management.Journal of translational medicine · 2022Article
- Internal Standard Triggered-Parallel Reaction Monitoring Mass Spectrometry Enables Multiplexed Quantification of Candidate Biomarkers in Plasma.Analytical chemistry · 2022Article
- Analytical Considerations of Large-Scale Aptamer-Based Datasets for Translational Applications.Cancers · 2022Review
- Light contamination in stable isotope-labelled internal peptide standards is frequent and a potential source of false discovery and quantitation error in proteomics.Analytical and bioanalytical chemistry · 2022Article
- Plasma protein biomarker model for screening Alzheimer disease using multiple reaction monitoring-mass spectrometry.Scientific reports · 2022Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors.
Funding
Abstract
High-throughput technologies can now identify hundreds of candidate protein biomarkers for any disease with relative ease. However, because there are no assays for the majority of proteins and de novo immunoassay development is prohibitively expensive, few candidate biomarkers are tested in clinical studies. We tested whether the analytical performance of a biomarker identification pipeline based on targeted mass spectrometry would be sufficient for data-dependent prioritization of candidate biomarkers, de novo development of assays and multiplexed biomarker verification. We used a data-dependent triage process to prioritize a subset of putative plasma biomarkers from >1,000 candidates previously identified using a mouse model of breast cancer. Eighty-eight novel quantitative assays based on selected reaction monitoring mass spectrometry were developed, multiplexed and evaluated in 80 plasma samples. Thirty-six proteins were verified as being elevated in the plasma of tumor-bearing animals. The analytical performance of this pipeline suggests that it should support the use of an analogous approach with human samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.